Abstract
Rats received therapeutically equivalent doses of either haloperidol (1.7–1.9 mg/kg/day), sulpiride (112–116 mg/kg/day) or clozapine (30–35 mg/kg/day) continuously for 4 weeks. Treatment with haloperidol, but not sulpiride or clozapine, caused inhibition of stereotyped behaviour induced by apomorphine (0.125–0.25 mg/kg SC). Following drug withdrawal for up to 7 days, haloperidol and sulpiride, but not clozapine treatment caused an exaggeration of stereotyped behaviour induced by apomorphine.
Bmax values for striatal 3H-spiperione binding were erevated in animals treated for 2 and 4 weeks with haloperidol, but not with sulpiride or clozapine. Following drug withdrawal, haloperidol, but not sulpiride or clozapine, treatment caused an increase in Bmax for striatal 3H-piperone binding.
Bmax values for striatal 3H-NPA binding revealed no change during haloperidol or clozapine treatment. Sulpiride treatment for 1 week caused an increase in Bmax for 3H-NPA binding, which returned to control levels at 2 and 4 weeks. Following drug withdrawal, there was an increase in Bmax for 3H-NPA binding in rats treated with haloperidol and sulpiride, but not clozapine.
On continuous treatment and following withdrawal from haloperidol, sulpiride, or clozapine the ability of dopamine to stimulate striatal adenylate cyclase activity did not differ from that in control animals.
Repeated administration of sulpiride or clozapine may not induce striatal dopamine receptor supersensitivity when given in clinically relevant doses, although haloperidol does.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alberts JL (1983) Survey presented at Symposium on Sulpiride, Paris
Allikmets LH, Zarkovsky AM, Nurk AM (1981) Changes in catalepsy and receptor sensitivity following chronic neuroleptic treatment. Eur J Pharmacol 75:145–147
Anden NE, Stock G (1973) Effect of clozapine on the turnover of dopamine in the corpus stratum and in the limbic system. J Pharm Pharmacol 25:346–348
Bannet J, Gillis S, Ebstein RP, Belmaker RH (1980) The effect of chronic sulpiride on striatal spiperone binding. Int Pharmacopsychiatry 15:334–337
Bartholini G (1976) Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J Pharm Pharmacol 28:429–433
Burki HR (1980) Inhibition of 3H-clozapine binding in rat brain after oral administration of neuroleptics. Life Sci 26:2187–2193
Burt DR, Creese I, Snyder SH (1977) Antipsychotic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196:326–328
Clement-Cormier YC, Kebabian JW, Petzold GL, Greengard P (1974) Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs. Proc Natl Acad Sci USA 71:1113–1117
Costall B, Naylor RJ (1975) Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacology 43:69–74
Costall B, Naylor RJ, Owen RT (1978) Behavioural correlates of modified dopaminergic/anticholinergic responses following chronic treatment with neuroleptic agents of differing activity spectra. Eur J Pharmacol 48:29–36
Creese I, Prosser T, Snyder SH (1978) Dopamine receptor binding: specificity, localisation and regulation by ions and guanyl nucleotides. Life Sci 23:495–500
Creese I, Stewart K, Snyder SH (1979a) Species variations in dopamine receptor binding. Eur J Pharmacol 60:55–66
Creese I, Usdin T, Snyder SH (1979b) Guanine nucleotides distinguish between two dopamine receptors. Nature 278:577–578
Fleminger S, Rupniak NMJ, Hall MD, Jenner P, Marsden CD (1983) Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors. Biochem Pharmacol 32:2921–2927
Fuxe K, Ogren S-O, Hall H, Agnati LF, Anderson K, Kohler C, Schwartz R (1980) Effect of chronic treatment with 1-sulpiride and haloperidol on central monoaminergic mechanisms. In: Cattabeni F, Racagni G, Spano PF, Costa E (eds) Long-term effects of neuroleptics. Raven Press, New York, Adv Biochem Psychopharmacol 24:193–197
Gerlach J, Koppelhuis P, Helweg E, Monrad A (1974) Clozapine and haloperidol in a single blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410–424
Gnegy M, Uzunov P, Costa E (1977) Participation of an endogenous Ca++-binding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors. J Pharmacol Exp Ther 202:558–564
Goldstein M, Lew JY, Asaro T, Ueta K (1980) Alterations in dopamine receptors: effect of lesion and haloperidol treatment. Commun Psychopharmacol 4:21–25
Hall MD, Jenner P, Marsden CD (1981) Characteristics of in vitro binding of 3H-N,n-propylnorapomorphine to rat striatal preparations. Neurosci Lett Suppl 7:363
Heal DJ, Green AR, Boullin DG, Grahame-Smith DG (1976) Single and repeated administration of neuroleptic drugs to rats: effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and l-tryptophan or l-dopa. Psychopharmacology 49:287–300
Jenner P, Hall MD, Murugaiah K, Rupniak N, Theodorou A, Marsden CD (1982) Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity. Biochem Pharmacol 31:325–328
Kobayashi RM, Fields JZ, Hruska RE, Beaumont K, Yamamura HI (1978) Brain neurotransmitter receptors and chronic antipsychotic drug treatment: a model for tardive dyskinesia. In: Usdin E (ed) Animal models in psychiatry. Pergamon Press, New York, pp 405–409
Leysen JE, Gommeren W (1981) Optimal conditions for 3H-apomorphine binding and anomalous equilibrium binding of 3H-apomorphine and 3H-spiperone to rat striatal membranes: involvement of surface phenomena versus multiple binding sites. J Neurochem 36:201–219
Leysen JE, Gommeren W, Laduron PM (1978) Spiperone: a ligand of choice for neuroleptic receptors. I. Kinetics and characteristics of in vitro binding. Biochem Pharmacol 27:307–316
Martindale (1982) The Extra Pharmacopoeia 28th Edition, EF Reynolds (ed). Pharmaceutical Press, London
Matz R, Rick W, Oh D, Thompson H, Gershon S (1974) Clozapine — a potential antipsychotic agent without extrapyramidal manifestations. Current Therapeutic Research 16:687–695
Miller R, Hiley CR (1974) Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 248:596–597
Miller RJ, Horn AS, Iversen LL (1974) The action of neuroleptic drugs on dopamine stimulated adenosine cyclic 3′,5′-monophosphate production in rat neostriatum and limbic forebrain. Mol Pharmacol 10:759–766
Racagni G, Bruno F, Bugatti A, Parenti M, Apud JA, Santini V, Carenzi G, Groppetti A, Cattabeni F (1980) Behavioural and biochemical correlates after haloperidol and clozapine long-term treatment. In: Catabeni G, Racagni G, Spano PF, Costa E (eds) Long-term effects of neuroleptics. Raven Press, New York. Adv Biochem Psychopharmacol 24:45–52
Rotrosen J, Friedman E, Gershon S (1975) Striatal adenylate cyclase activity following reserpine and chronic chlorpromazine administration in rats. Life Sci 17:563–568
Sayers AC, Burki HP, Ruch W, Asper H (1975) Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacology 41:97–104
Seeger TF, Thal L, Gardner EL (1982) Behavioural and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol. Psychopharmacology 76:182–187
Sibley DR, Creese I (1980) Pseudo non-competitive agonist interactions with dopamine receptors. Eur J Pharmacol 65:131–133
Simpson GM, Varga E (1974) Clozapine — a new antipsychotic agent. Current Therapeutic Research 16:679–686
Smith RC, Davis JM (1976) Behavioural evidence for supersensitivity after chronic administration of haloperidol, clozapine and thioridazine. Life Sci 19:725–732
Snyder SH, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 31:58–61
Stoof JC, Kebabian JW (1981) Opposing roles for D1 and D2 dopamine receptors in efflux of cylic AMP from rat neostriatum. Nature 294:366–368
Tarsy D, Baldessarini RJ (1974) Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with synaptic function of catecholamines. Neuropharmacology 13:927–940
Theodorou AE, Hall MD, Jenner P, Marsden CD (1980) Cation regulation differentiates specific binding of 3H-sulpiride and 3H-spiperone to rat striatal preparations. J Pharm Pharmacol 32:441–444
Titeler M, Seeman P (1980) Radioreceptor labeling of pre- and post-synaptic dopamine receptors. In: Cattabeni F, Racagni G, Spano PF, Costa E (eds) Long-term effects of neuroleptics. Raven Press, New York. Adv Biochem Psychopharmacol 24:159–166
Trabucchi M, Memo M, Battaini F, Regiani A, Spano PF (1980) Effect of long-term treatment with haloperidol and sulpiride on different types of dopaminergic receptors. In: Cattabeni F, Racagni G, Spano PF, Costa E (eds) Long-term effects of neuroleptics. Raven Press, New York, Adv Biochem Psychopharmacol 24:275–282
von Voigtlander PF, Losey EG, Triezenberg HJ (1975) Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. J Pharmacol Exp Ther 193:88–94
Wiesel F-A, Alfredsson G, Ehrnebo M, Sedvall G (1980) The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 17:385–391
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rupniak, N.M.J., Kilpatrick, G., Hall, M.D. et al. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology 84, 512–519 (1984). https://doi.org/10.1007/BF00431458
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00431458